UNITID INTRODUCES THE SCREENING OF MYELOGENOUS LEUKAEMIA BY USE OF XPERT BCR –ABL MONITOR UNITID recently started screening for the Philadelphia chromosome.

Slides:



Advertisements
Similar presentations
By Gracie Canales August 10, 2010
Advertisements

Dr. Thaweesak Tirawatnapong Chula Medical Research Center (Chula MRC)
Identification and RQ-PCR monitoring of CML patients with rare variant BCR-ABL transcripts Chris Bowles West Midlands Regional Genetics Laboratory.
Imatinib Resistance Geoffrey L. Uy, M.D. Associate Professor of Medicine Division of Oncology.
The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.
I’ve just been diagnosed with CML. Could you answer my questions?
Chronic leukaemias Chronic myelogenous leukaemia Chronic myelogenous leukaemia Chronic lymphocytic leukaemia Chronic lymphocytic leukaemia.
Droplet digital PCR Overview and applications
Carolyn A. Ragland August Hepatitis C *Paraenterally transmitted Contact with infected blood / blood products Blood transfusions – no longer the.
Molecular Medicine. Focus on Cancer Most chemotherapies were developed before the human genome was sequenced Many are alkylating agents that attach methyl.
Oncogenes and Chromosomal Aberrations The Story of Abl and the Philadelphia Chromosome.
LS/MW MT 417 – Clinical Hematology II Manual/Special Tests Unit Leukocyte Alkaline Phosphatase Exercise LAP Questions KEY.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Anticancer Therapy: Kinase Inhibitors Charles Harrell.
Rakesh Biswas MD Professor, Medicine, People's College of Medical Sciences, Bhopal, India Lecture first conceived and delivered to medicine undergrads.
Converting BCR-ABL1 to the International Scale: Standardizing the Measurement of Relative Gene Expression Charles E. Hill Emory University School of Medicine.
Marty O’Neill II Carmen Banea
Chronic Myeloid Leukemia Leukemia ALL, AML, CLL ALL, AML, CLL Chronic Myelogenous Leukemia Chronic Myelogenous Leukemia –Cancer of the granulocytes or.
CHRONIC MYELOID LEUKAEMIA Dr Rosline Hassan Department of Haematology School of Medical Sciences Universiti Sains Malaysia.
Tabuk University Faculty of Applied Medical Sciences
Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist Hagop M. Kantarjian, MD Chairman; Professor, Department of Leukemia.
Fusion Genes in Cancer Wednesday, June 27th. Outline: Transcription Fusion genes Examples of fusion genes in cancer Summary and conclusions.
Products of haematopoiesis. Leukaemia, the current hypothesis Defect in maturation of white blood cells-may involve a block in differentiation and/or.
Livin in Prognosis of Childhood ALL Livin- member of inhibitor of apoptosis proteins (IAP). – IAP- acts on effector and initiator caspases Function of.
MEDICAL TESTING Doctor requires information Patient sample collection

Myeloprolifrative disorders -Chronic Myelogenouse Leukemia - Primary Poly Cythemia ( vira ) - Essential Thrombocythemia - Myelofibrose Myeloid Methaplasia.
Chapter 4 Cellular Oncogenes ~ Mar 22, 2007.
Pei Lin, MD Department of Hematopathology UT M.D. Anderson Cancer Center, Houston, TX Monitoring of Minimal Residual Disease Principles and Applications.
Normal haemopoiesis. ABNORMALITIES IN THE HEMOPOIETIC SYSTEM CAN LEAD TO HEMOGLOBINOPATHIES HEMOPHILIA DEFECTS IN HEMOSTASIS/THROMBOSIS HEMATOLOGICAL.
Genetic Mutations that Lead to Chronic Myelogenous Leukemia: Causes and Treatments Marty O’Neill II & Carmen Banea
Here are some CML slides that may be helpful for your presentation.
Julia Robbins August 11, Objectives Clinical Significance of MRSA in Healthcare Setting Principle of assay Assay Procedure Assay Perfomance.
Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.
HCV PCR By Henrietta Orji July 31 st, 2010 Hepatitis C Virus by Polymerase Chain Reaction.
Interesting Developments. Historic trends in biotech fields.
Case Study MICR Hematology Spring, 2011 Case # 5 Hee Jin Kim, Hooman Nikizad and Arthur Omuro.
Current use of imatinib in the treatment of chronic myeloid leukaemia Michael O’Dwyer Haematologica March 2003.
Treatment of CML. Goal of Therapy Complete molecular remission and cure – Achieve prolonged, durable, nonneoplastic, nonclonal hematopoiesis, – Eradication.
Dr Nauman Butt – Royal Liverpool University Hospital CML Patient Seminar - 14 th November 2015 What is CML? How do we treat it? Get up to speed…
Molecular Monitoring in CML the process and questions we can answer Letizia Foroni.
Molecular Modeling 1. Introduction to Computational Molecular Physics 2. Molecular Mechanics 3. Conformation Searching 4. Molecular Orbital Methods 5.
Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.
What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of.
The Factor II (Prothrombin) G20210A Detection and Genotyping
Chronic Myeloid Leukemia
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Identification of a Novel TP53 Cancer Susceptibility.
INTRODUCTION & OBJECTIVES Introduction: The carcinogenesis of hepatocellular carcinoma (HCC) is a multifactorial, multistep and complex process. Its prognosis.
Resistance to Targeted Therapy in Chronic Myelogenous Leukemia Andreas Hochhaus, Philipp Erben, Thomas Ernst, and Martin C. Mueller Seminars in Hematology.
Chronic myeloid leukaemia
Shah N et al. Proc ASH 2010;Abstract 206.
HCV by PCR Neelam Gajjar 7/26/2009.
CLINICAL PROGRESSION INTRODUCTION METHOD CONCLUSION REFERENCES
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Assistant Prof. Dr. Nibras Saleam Al-Ammar PhD in Clinical Immunology
HS 4160 Critical Scientific Analysis
Leukemia Human Disease Asma Siddique BIOT 412.
Imatinib – where are we now. What about generic imatinib
CASE STUDY Leukemia.
Β-Glucuronidase Is an Optimal Normalization Control Gene for Molecular Monitoring of Chronic Myelogenous Leukemia  Joong Won Lee, Qiaofang Chen, Daniel.
Polymerase Chain Reaction (PCR)
The (4;11)(q21;p15) Translocation Fuses the NUP98 andRAP1GDS1 Genes and Is Recurrent in T-Cell Acute Lymphocytic Leukemia by Damian J. Hussey, Mario Nicola,
Lauren M. Stanoszek, Erin L. Crawford, Thomas M. Blomquist, Jessica A
BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia  Richard D. Press, Suzanne Kamel-Reid,
MicroRNAs: From Decay to Decoy
Molecular Monitoring of Chronic Myelogenous Leukemia
Molecular Monitoring of Chronic Myeloid Leukemia
CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST
RealTime-PCR.
Presentation transcript:

UNITID INTRODUCES THE SCREENING OF MYELOGENOUS LEUKAEMIA BY USE OF XPERT BCR –ABL MONITOR UNITID recently started screening for the Philadelphia chromosome by use of XPERT BCR-ABL on 22 nd September The Xpert BCR-ABL Monitor Assay is a real-time RT-PCR (reverse transcription- polymerase chain (Reaction) assay intended as an aid in the monitoring of the BCR-ABL mRNA transcript in peripheral blood of patients with chronic myelogenous leukemia (CML). The Xpert BCR-ABL Monitor Assay is an automated test for quantifying the amount of BCR-ABL transcript as a ratio of BCR-ABL/ABL. The assay is performed on Cepheid GeneXpert Instrument Systems. The systems consist of an instrument, computer, and preloaded software for running tests and viewing the results. The systems require the use of single-use, disposable GeneXpert cartridges that hold the RT-PCR and PCR reagents and host the RT- PCR and PCR processes CML is one of the most common hematologic malignancies and accounts for 15-20% of all cases of leukemia. The incidence of CML is approximately 1.6/100,000, meaning 1 out of every 635 men and women will be diagnosed with CML during their lifetime. More than 95% of patients with CML have the distinctive Philadelphia chromosome (Ph1) that results from a reciprocal translocation between the long arms of chromosomes 9 and 22.2 The translocation involves the transfer of the Abelson or ABL1 (ABL) gene on chromosome 9 to the breakpoint cluster region (BCR) of chromosome 22, resulting in a fused BCR-ABL1 (BCR-ABL) gene. The fusion gene produces BCR- ABL, a tyrosine kinase with deregulated activity that plays a key role in the development of CML.3 The clinical utility of monitoring BCR-ABL mRNA levels by RT-PCR has been established in the International Randomized Study of Interferon and STI571 (IRIS),in which patient results were normalized under a standardized baseline common to the three laboratories participating in the trial. Subsequently, it was proposed that BCR-ABL monitoring assays conform to an international scale (IS) and should be anchored to two values defined in the IRIS trial, thereby allowing results to be expressed on a common scale. The first of these is the standardized baseline which represents 100% IS, and the second is a prognostically favorable 3-log reduction from the standardized baseline which represents 0.10% IS. In this fashion, IS-standardized molecular testing can provide an essential aid for clinicians to manage their CML patients’ disease. Speaking during the launch,Prof Mwanda,the Director of UNITID and also the prof of Haematology and Blood Transfusion noted that this is a breakthrough in the management of Leukaemia since this is one of its kind in East and central Africa.The test is expected to cost Ksh !6000.This gives a package of the Bone marrow aspirate,Full blood count and BCR-ABL.The results are ready within 3 hours of sample reception. Collect blood specimens in EDTA tubes, sodium citrate tubes, or PAX gene R Blood RNA tubes. Do not use heparin as the anticoagulant because it can inhibit the PCR reaction. Store blood specimens at 2-8 oC and the test should be completed within 48 hours after collection. For more info contact UNITID at , or Fred Mose